WHIPPANY, N.J. – March 16, 2026 – A novel study has demonstrated a significant benefit for patients with chronic kidney disease (CKD) who do not have diabetes. Bayer announced today that its drug, KERENDIA® (finerenone), met the primary endpoint in a Phase III clinical trial, FIND-CKD, evaluating its effectiveness in this patient population.
The trial, which involved adult patients with non-diabetic CKD, showed a statistically significant improvement in the estimated glomerular filtration rate (eGFR) slope compared to placebo, from baseline to Month 32. EGFR is a key measure of kidney function, and this finding suggests KERENDIA may help sluggish the progression of kidney disease. This is particularly essential as CKD can lead to serious health complications and ultimately kidney failure.
FIND-CKD (NCT05047263) is the largest Phase III study to date focused on non-diabetic CKD, expanding the clinical data for KERENDIA to include both diabetic and non-diabetic patients. This success marks the fifth consecutive Phase III clinical trial where KERENDIA has met its primary endpoint, encompassing a broad clinical program involving over 20,000 patients with various heart and kidney conditions.
Currently, KERENDIA is approved by the U.S. Food and Drug Administration (FDA) for adults with CKD associated with type 2 diabetes (T2D) and heart failure with left ventricular ejection fraction (HF LVEF) ≥40%. Bayer plans to submit the data from the FIND-CKD study to the FDA, seeking to broaden the drug’s indication to include patients with non-diabetic CKD.
According to the study results, the safety profile of KERENDIA in the FIND-CKD trial was consistent with previously established safety data. The clinical data from FIND-CKD will be presented at an upcoming scientific conference.
Researchers defined the primary efficacy outcome as the mean annual rate of change in eGFR from baseline to Month 32, a validated surrogate endpoint for kidney disease progression.
